Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
Context: Although trastuzumab is a highly effective and selective targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the drug-induced cardiotoxicity may confine its usefulness in patients. Aim: To explore risk factors associated with the development of cardi...
Saved in:
Main Authors: | Wesam Abdel-Razaq (Author), Mohammed Alzahrani (Author), Majed Al Yami (Author), Faisal Almugibl (Author), Mohammed Almotham (Author), Razan Alregaibah (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
by: ZiYan Yang, et al.
Published: (2021) -
Metastatic dermatosis in breast carcinoma on adjuvant trastuzumab: Is skin a sanctuary site in human epidermal growth factor receptor-2-amplified disease?
by: Amit Sehrawat, et al.
Published: (2018) -
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023) -
Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
by: Liyi Zhang
Published: (2021) -
Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18-21 mutations
by: Nikolova Dafina, et al.
Published: (2022)